New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
09:19 EDTCI, QCOR, MNKReimbursement for Questcor Acthar by Cigna mostly unchanged, says CRT Capital
After Cigna (CI) updated its coverage policy for Questcor's (QCOR) Acthar, CRT Capital thinks the new rules may be viewed as more restrictive than previously. However, the firm thinks that Cigna's reimbursement policies for Actharfor indications other than MS flares are mostly unchanged. It keeps a Fair Value rating on Mallinkrodt, which has agreed to buy Questcor.
News For MNK;QCOR;CI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
09:16 EDTMNKOn The Fly: Pre-market Movers
Subscribe for More Information
07:01 EDTMNKMallinckrodt reports Q4 adjusted EPS $1.68, consensus $1.41
Reports Q4 revenue $789.3M, consensus $757.86M.
November 18, 2014
15:21 EDTMNKNotable companies reporting before tomorrow's open
Subscribe for More Information
November 14, 2014
17:27 EDTMNKPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
16:52 EDTCIGreenlight Capital gives quarterly update on stakes
Subscribe for More Information
09:51 EDTMNKMallinckrodt management to meet with Oppenheimer
Meeting to be held in Europe on November 20 hosted by Oppenheimer.
November 13, 2014
10:44 EDTMNKMallinckrodt news on generic Concerta positive for Actavis, says BMO Capital
Subscribe for More Information
08:20 EDTMNKMallinckrodt could be down $6-$8 on FDA reclassification, says UBS
Subscribe for More Information
06:11 EDTMNKMallinckrodt responds to FDA expected reclassification of methylphenidate ER
Mallinckrodt has been informed by the FDA that the agency has reason to believe that the company’s methylphenidate hydrochloride extended-release, or ER, tablets, USP may not be therapeutically equivalent to the category reference drug Concerta. As a result, the agency indicated that it has reclassified Mallinckrodt’s ANDA 202608 for methylphenidate ER dosage strengths of 27mg, 36 mg and 54 mg from AB to BX. The agency said that this change was based on the application of its new Draft Guidance for determining bioequivalence of methylphenidate hydrochloride products just published on November 6, 2014. Although the Draft Guidance has an open comment period through January 5, 2015, the agency nevertheless confirmed that this change would be reflected on November 13, 2014 in the on-line Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Mallinckrodt strongly believes its methylphenidate ER products are safe and effective when used in accordance with the approved labels. Mark Trudeau, president and CEO of Mallinckrodt stated, “We believe that the FDA’s actions are not supported by sound scientific evidence and not consistent with the best interests of patients." Mallinckrodt methylphenidate ER products have consistently met all quality specifications and the regulatory requirements originally defined by the FDA, and in the 21 months since launch more than 88M doses of these products have been prescribed. In that time, and across all of those patient exposures, the company has received only 68 confirmed adverse events related to a lack of efficacy when the patient switched from the reference listed drug to the company’s methylphenidate ER products.
November 12, 2014
08:58 EDTCIManaged Care earnings risk low from King vs. Burwell, says Leerink
Leerink believes the Supreme Court decision to the King vs. Burwell case carries low earnings risk for Managed Care companies. The case to determine the legality of Exchange subsidies administered by the Federal Government carries less than 2% and 3% of earnings risk for 2014 and 2015 estimates, respectively, Leerink believes. The firm says Humana (HUM) and Cigna (CI) are currently losing money on Exchanges, and thus could benefit from any Federal Exchange membership loss. Leerink lists Aetna (AET), Centene (CNC), WellPoint (WLP) and Molina Healthcare (MOH) as being most impacted.
November 11, 2014
12:55 EDTCIWorkarounds to likely protect insurers from Supreme Court decision, says Wedbush
Subscribe for More Information
November 10, 2014
06:29 EDTCICigna to restructure HIV prescription drug benefits, WSJ reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use